Abivax SA (0RA9) Stock Statistics & Valuation Metrics

Abivax SA has a market cap or net worth of €304.37M. The enterprise value is €378.92M.

Abivax SA has 63.42M shares outstanding. The number of shares has decreased by -2.65% in one year.

Abivax SA’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Abivax SA is ―. Abivax SA’s PEG ratio is ―.

In the last 12 months, Abivax SA had revenue of €9.03M and earned -€177.43M in profits. Earnings per share was -€3.21.

In the last 12 months, operating cash flow was -€154.71M and capital expenditures -€353.00K, giving a free cash flow of -€155.06M billion.

Abivax SA pays an annual dividend of , resulting in a dividend yield of

Abivax SA upcoming earnings date is Jun 2, 2025, Before Open.

Abivax SA as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Abivax SA has paid -€4.92M in taxes.

Abivax SA EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Abivax SA has €222.32M in cash and marketable securities with €113.36M in debt, giving a net cash position of -€108.95M billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Abivax SA is €17.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy